Editas Medicine (EDIT) announced the nomination of its lead in vivo development candidate, EDIT-401, an experimental, potential best-in-class, one-time therapy designed to significantly reduce LDL cholesterol levels. “Today’s nomination of EDIT-401 as our lead in vivo development candidate is a significant milestone in our long-term vision to lead the field of in vivo programmable gene editing,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “At Editas Medicine, we believe in vivo is the future of medicine. With EDIT-401, we’re advancing our differentiated upregulation strategy to develop a next-generation medicine that can deliver lasting impact for patients.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability
- Editas Medicine price target raised to $5 from $3 at H.C. Wainwright
- Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch
- Editas Medicine Reports Q2 2025 Progress and Financials
- Editas Medicine price target raised to $6 from $4 at Baird